{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:40:03Z","timestamp":1746186003341,"version":"3.40.4"},"reference-count":108,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"Serbian Ministry of Science, Technological Development and Innovations","award":["451-03-65\/2024\u201303\/200111"],"award-info":[{"award-number":["451-03-65\/2024\u201303\/200111"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2025,5,4]]},"DOI":"10.1080\/17425255.2025.2473439","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T03:32:03Z","timestamp":1740799923000},"page":"535-550","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Preventable serious drug-disease interactions of reserve antibiotics"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1519-8828","authenticated-orcid":false,"given":"Slobodan M.","family":"Jankovi\u0107","sequence":"first","affiliation":[{"name":"University of Kragujevac","place":["Kragujevac, Serbia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sne\u017eana V.","family":"Jankovi\u0107","sequence":"additional","affiliation":[{"name":"University of Kragujevac","place":["Kragujevac, Serbia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dobrivoje","family":"Stojadinovi\u0107","sequence":"additional","affiliation":[{"name":"University of Kragujevac","place":["Kragujevac, Serbia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00707"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000486753"},{"key":"e_1_3_5_5_1","unstructured":"The. WHO AWaRe classification of antibiotics for evaluation and monitoring of use [internet]. 2023 [cited 2024 Jul 17]. Available from: https:\/\/qualityhealthservices.who.int\/quality-toolkit\/qt-catalog-item\/the-2023-who-aware-classification-of-antibiotics-for-evaluation-and-monitoring-of-use"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1856-1"},{"key":"e_1_3_5_7_1","unstructured":"The WHO AWaRe (access watch reserve) antibiotic book [Internet]. [cited 2024 Oct 26]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240062382"},{"key":"e_1_3_5_8_1","unstructured":"Drugs.com [Internet]. [Aztreonam monograph for professionals. [cited 2024 Oct 26]. Available from: https:\/\/www.drugs.com\/monograph\/aztreonam.html"},{"key":"e_1_3_5_9_1","unstructured":"Azactam 1g powder for solution for injection or infusion-vial - summary of product characteristics (SmPC) - (emc) [Internet]. [cited 2024 Oct 26]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/3773\/smpc"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1550059420917842"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz857"},{"key":"e_1_3_5_12_1","unstructured":"Zinforo 600 mg powder for concentrate for solution for infusion - summary of product characteristics (SmPC) - (emc) [Internet]. [cited 2024 Oct 26]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/4297\/smpc"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis559"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-005-0021-y"},{"key":"e_1_3_5_15_1","unstructured":"Managed Healthcare Executive [Internet]. FDA approves new antibacterial drug Avycaz. Available from 2015 [cited 2024 Oct 26]. Available from: https:\/\/www.managedhealthcareexecutive.com\/view\/fda-approves-new-antibacterial-drug-avycaz"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/3527608001.ch1"},{"key":"e_1_3_5_17_1","unstructured":"Zavicefta 2 g\/0.5g powder for concentrate for solution for infusion - summary of product characteristics (SmPC) - (emc) [Internet]. [cited 2024 Oct 26]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/2465\/smpc"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.11.031"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13796"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2420"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1988.00520330010002"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.297.6652.858-a"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1991.tb04302.x"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.4.333"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1994.00420050158014"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/089686089401400424"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.3.369.32100"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000077370"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650600671753"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.4103\/0971-4065.144426"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.4103\/0259-1162.159773"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/0897190015608503"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.2250"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8936478"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0897190021989931"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2022.08.011"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.2739\/kurumemedj.MS6934009"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-023-02167-9"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2019.1667229"},{"key":"e_1_3_5_40_1","unstructured":"Zevtera 500 mg powder for concentrate for solution for infusion - summary of product characteristics (SmPC) - (emc) [Internet]. [cited 2024 Oct 27]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/9164\/smpc"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.03.010"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00515-19"},{"key":"e_1_3_5_43_1","unstructured":"Drugs.com [Internet]. [FDA approves zerbaxa (ceftolozane\/tazobactam) for complicated intra-Abdominal\/Urinary tract infections. [cited 2024 Oct 27]. Available from: https:\/\/www.drugs.com\/newdrugs\/fda-approves-zerbaxa-ceftolozane-tazobactam-complicated-intra-abdominal-urinary-tract-infections-4130.html"},{"key":"e_1_3_5_44_1","unstructured":"Zerbaxa 1 g\/0.5 g powder for concentrate for solution for infusion - summary of product characteristics (SmPC) - (emc) [Internet]. [cited 2024 Oct 27]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/5009\/smpc"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02291-19"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2015.1093933"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.6.5.593"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.120.000020"},{"key":"e_1_3_5_49_1","unstructured":"Colomycin 1 million international units (IU) powder for solution for injection infusion or inhalation - summary of product characteristics (SmPC) - (emc) [Internet]. [cited 2024 Oct 27]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/1094\/smpc"},{"key":"e_1_3_5_50_1","unstructured":"PRODUCT MONOGRAPH. POLYMYXIN B for INJECTION USP powder for solution polymyxin B 50 mg\/vial (500 000 units) (as polymyxin B sulphate). Available from: https:\/\/pdf.hres.ca\/dpd_pm\/00014719.PDF"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1966.00290160026006"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-023-03334-8"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.JJID.2014.501"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2017.11.022"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-205332"},{"key":"e_1_3_5_56_1","unstructured":"L\u00edrio M Aguiar G Sp\u00ednola SU et al. Colistin induced neurotoxity: a case report and review of literature. Rev Bras Neurol. 2018;54(4):30\u20133."},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omab080"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1969.03150240119022"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.4103\/2229-5151.141487"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.31080\/ASPS.2020.04.0551"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics8010031"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1966.03100150127040"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1342419"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.18231\/j.ijirm.2021.052"},{"issue":"1","key":"e_1_3_5_65_1","first-page":"1008","article-title":"Polymyxin B induced hypotension","volume":"2","author":"Raghavapuram N","year":"2022","unstructured":"Raghavapuram N, Narmada T. Polymyxin B induced hypotension. World J Clin Case Rep Case Ser. 2022;2(1):1008.","journal-title":"World J Clin Case Rep Case Ser"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1159\/000109868"},{"key":"e_1_3_5_67_1","unstructured":"Daptomycin 500mg powder for solution for Injection\/Infusion - summary of product characteristics (SmPC) - (emc) [Internet]. [cited 2024 Oct 27]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/12263\/smpc"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00968-x"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.8.8.1223"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.07.009"},{"issue":"8","key":"e_1_3_5_71_1","first-page":"42","article-title":"Daptomycin and incidence of elevated creatinine phosphokinase (CPK) levels: a case report and case series review","volume":"72","author":"Kishimoto E","year":"2013","unstructured":"Kishimoto E, Ota L, Solomon C. Daptomycin and incidence of elevated creatinine phosphokinase (CPK) levels: a case report and case series review. Hawaii J Med Public Health. 2013;72(8 Suppl 3):42.","journal-title":"Hawaii J Med Public Health"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29764"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1298"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38285"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02910-14"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-022-2648-5"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac125"},{"issue":"8","key":"e_1_3_5_78_1","first-page":"285","article-title":"A case report on faropenem induced focal seizures","volume":"8","author":"Shariff Z","year":"2023","unstructured":"Shariff Z, Vithya T, Prasad S. A case report on faropenem induced focal seizures. Int J Innov Sci Res Technol. 2023;8(8):285\u2013287.","journal-title":"Int J Innov Sci Res Technol"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2009.01139.x"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14122"},{"key":"e_1_3_5_81_1","unstructured":"PRODUCT MONOGRAPH for intravenous fosfomycin (Fosfomycin disodium). InfectoPharm Arzneimittel und Consilium GmbH. 2020. Available from: https:\/\/en.infectopharm.com\/wp-content\/uploads\/Product-Monograph-Intravenous-Fosfomycin.pdf"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1080\/003655401750174200"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-015-0092-8"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.09.002"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2014.07.005"},{"key":"e_1_3_5_86_1","unstructured":"Linezolid 2mg\/ml solution for infusion - summary of product characteristics (SmPC) - (emc) [Internet]. [cited 2024 Oct 28]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/7300\/smpc"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342130-00004"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1338902"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-024-00458-6"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1086\/379012"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.5.746"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000751"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1086\/430441"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2008.20.6.766"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.20"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.20233411S11107b"},{"key":"e_1_3_5_97_1","unstructured":"Drugs@FDA: FDA-Approved Drugs [Internet]. [cited 2024 Oct 28]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=021131"},{"key":"e_1_3_5_98_1","unstructured":"Sivextro 200 mg powder for concentrate for solution for infusion - summary of product characteristics (SmPC) - (emc) [Internet]. [cited 2024 Oct 28]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/1921\/smpc"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01099-7"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1097\/IPC.0000000000000623"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-020-04121-1"},{"key":"e_1_3_5_102_1","unstructured":"Tigecycline 50 mg powder for solution for infusion - summary of product characteristics (SmPC) - (emc) [Internet]. [cited 2024 Oct 28]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/9232\/smpc"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07258-w"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.23937\/2474-3658\/1510060"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.924556"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-019-0321-y"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.90.EP1103"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015399"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06050-1"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000710"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2025.2473439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:24:47Z","timestamp":1746185087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2025.2473439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":108,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,4]]}},"alternative-id":["10.1080\/17425255.2025.2473439"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2025.2473439","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"type":"print","value":"1742-5255"},{"type":"electronic","value":"1744-7607"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}